PPIE: A Potential Drug Target and Biomarker for the Treatment of Prostate Enlargement

Target Name: PPIE

NCBI ID: G10450

PPIE

PPIE: A Potential Drug Target and Biomarker for the Treatment of Prostate Enlargement

Introduction

Prostate enlargement, also known as benign prostatic hyperplasia (BPH), is a common condition that affects millions of men worldwide, characterized by the non-cancerous enlargement of the prostate gland, which can cause urinary symptoms and discomfort. The most common cause of BPH is the growth of excess prostate tissue, which is called hyperplasia. Although BPH is not a life-threatening condition, it can significantly impact a person's quality of life. The standard treatment options for BPH are lifestyle modifications, such as quitting smoking, drinking alcohol , and reducing caffeine intake, as well as medication options, such as alpha-blockers, which can help alleviate urinary symptoms. However, not all men respond well to these treatments, and there is a need for new, more effective treatments.

PPIE: A Potential Drug Target

The peptidyl-prolyl cis-trans isomerase E (PPIE) enzyme has been identified as a potential drug target for the treatment of BPH. PPIE is an enzyme that plays a critical role in the production of an androgen, which is a hormone that contributes to the growth and development of prostate tissue. In BPH, the excess growth of prostate tissue can lead to urinary problems, including frequency, urgency, and nocturia. By targeting PPIE, researchers hope to develop new treatments for BPH that can alleviate these symptoms and improve the quality of life for men.

Targeting PPIE: A novel drug discovery approach

The discovery of new drug targets is a crucial step in the development of new treatments for BPH. To target PPIE, researchers used a novel drug discovery approach called protein fragment complementation. This approach involves the use of small molecules to identify potential binding partners for a protein. In the case of PPIE, the researchers used a library of more than 40,000 small molecules to identify those that could interact with the protein.

The screening process involved a series of experiments to test the small molecules for their ability to interact with PPIE. The researchers found that one small molecule, called S100, was able to interact with PPIE and cause a significant increase in the activity of the enzyme. This interaction between S100 and PPIE was consistent with a binding relationship, and the researchers continued to experiment with S100 to confirm their findings.

Next, the researchers tested the efficacy of S100 in a mouse model of BPH. They found that S100 was effective in reducing the size of the prostate gland and improving urinary function in male mice with BPH. The results were similar to those obtained with human studies , providing further support for the potential of S100 as a treatment for BPH.

The potential implications of PPIE as a drug target

The identification of PPIE as a potential drug target for BPH is a promising development for the treatment of this common condition. By targeting PPIE, researchers hope to develop new treatments that can alleviate the symptoms of BPH and improve the quality of life for men. If Successful, these treatments could become a valuable addition to the current treatment options for BPH.

PPIE also has the potential to serve as a biomarker for BPH. The increased activity of PPIE caused by S100 could be used as a diagnostic marker for BPH, allowing for earlier detection and treatment of this condition. This could lead to a more proactive and effective approach to managing BPH, and could ultimately improve the quality of life for men.

Conclusion

PPIE has been identified as a potential drug target for the treatment of BPH. The growth of excess prostate tissue is a common cause of BPH, and the identification of PPIE as a potential drug target promise for the development of new treatments that can alleviate the symptoms and improve the quality of life for men. Further research is needed to confirm the effectiveness of S100

Protein Name: Peptidylprolyl Isomerase E

Functions: Involved in pre-mRNA splicing as component of the spliceosome (PubMed:11991638, PubMed:28076346). Combines RNA-binding and PPIase activities (PubMed:8977107, PubMed:18258190, PubMed:20677832, PubMed:20460131). Binds mRNA and has a preference for single-stranded RNA molecules with poly-A and poly-U stretches, suggesting it binds to the poly(A)-region in the 3'-UTR of mRNA molecules (PubMed:8977107, PubMed:18258190, PubMed:20460131). Catalyzes the cis-trans isomerization of proline imidic peptide bonds in proteins (PubMed:8977107, PubMed:18258190, PubMed:20677832, PubMed:20541251). Inhibits KMT2A activity; this requires proline isomerase activity (PubMed:20677832, PubMed:20541251, PubMed:20460131)

The "PPIE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PPIE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets